Clinical Trial Update: TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients [Phase 2]

View source ↗

Summary

A Phase 2 study (TMC114-C202) assessing safety, efficacy, and tolerability of TMC114 (darunavir) boosted with low-dose ritonavir in HIV-1 infected patients; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Norvir (ritonavir)
• PREZISTA (darunavir)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV Infections | Phase 2 | Status: COMPLETED